Anti-glutamic acid decarboxylase antibodies-associated cerebellar ataxia: A treatable ataxia
Annals of Movement Disorders · 2024-01 · 7 (1) · 13-18
DOI: 10.4103/aomd.aomd_23_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Movement Disorders, online erschienen am 21.03.2024. Verfasst von Rohan Mahale und 10 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Anti-glutamate decarboxylase 65 antibody-associated cerebellar ataxia (anti-GAD65Ab-associated CA) is the most widely studied immune-mediated CA. There are few case series evaluating the clinical, radiological, treatment profile, and outcome of anti-GAD65Ab-associated CA.
Objective
To study the clinical, radiological profile, associated neoplasm, treatment outcome, and prognosis in patients diagnosed with anti-GAD65Ab-associated CA.
Methods
A retrospective descriptive analysis of a cohort of patients diagnosed with anti-GAD65Ab-associated CA was performed and analyzed.
Results
Thirteen patients were selected for the analysis with female predominance (70%). The mean age at presentation was 47.5 ± 11.1 years (range, 29–65 years), and the median duration of the symptoms was 4 months. All 13 patients (100%) had gait ataxia. Ten patients had limb ataxia along with gait ataxia (75%). Seven patients had cerebellar dysarthria (54%). Four patients (31%) had gaze-evoked jerky nystagmus. Five patients (39%) were diagnosed with type 2 diabetes mellitus, and one patient had hypothyroidism in addition to type 2 diabetes mellitus. Brain magnetic resonance imaging was normal in seven (54%) patients, and pure cerebellar atrophy was observed in six patients. One patient was detected with a colon neoplasm. All 13 patients received intravenous methylprednisolone, followed by oral steroids over 3 months. Six patients (50%) received plasma exchange along with intravenous methylprednisolone. Favorable outcomes (modified Rankin scale score ≤2) were observed in five patients and poor outcomes in two; six patients were lost to follow-up after the first admission.
Conclusion
Anti-GAD65Ab-associated CA presents as subacute to chronic progressive CA with a favorable outcome with immunotherapy. Anti-GAD antibodies should be assessed in serum or cerebrospinal fluid in patients presenting subacute to chronic sporadic CA. The occurrence of a systemic neoplasm is rare in anti-GAD65Ab-associated CA.
Zitieren
APA
Mahale, R., M, S., Mahadevan, A., Kamble, N., Holla, V., Mundlamuri, R., Vengalil, S., M, N., Nalini, A., Pal, P. K., & Yadav, R. (2024). Anti-glutamic acid decarboxylase antibodies-associated cerebellar ataxia: A treatable ataxia. Annals of Movement Disorders, 7(1), 13-18. https://doi.org/10.4103/aomd.aomd_23_23
Vancouver
Mahale R, M S, Mahadevan A, Kamble N, Holla V, Mundlamuri R, et al. Anti-glutamic acid decarboxylase antibodies-associated cerebellar ataxia: A treatable ataxia. Annals of Movement Disorders. 2024;7(1):13-18. doi:10.4103/aomd.aomd_23_23
BibTeX
@article{Mahale2024,
author = {Mahale, Rohan and M, Sandeep and Mahadevan, Anita and Kamble, Nitish and Holla, Vikram and Mundlamuri, Ravindranadh and Vengalil, Seena and M, Netravathi and Nalini, Atchayaram and Pal, Pramod Kumar and Yadav, Ravi},
title = {Anti-glutamic acid decarboxylase antibodies-associated cerebellar ataxia: A treatable ataxia},
journal = {Annals of Movement Disorders},
year = {2024},
volume = {7},
number = {1},
pages = {13--18},
doi = {10.4103/aomd.aomd_23_23}
}
EUVIMED